GB946579A - Improvements in or relating to steroids and the manufacture thereof - Google Patents
Improvements in or relating to steroids and the manufacture thereofInfo
- Publication number
- GB946579A GB946579A GB38029/62A GB3802962A GB946579A GB 946579 A GB946579 A GB 946579A GB 38029/62 A GB38029/62 A GB 38029/62A GB 3802962 A GB3802962 A GB 3802962A GB 946579 A GB946579 A GB 946579A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- formula
- phosphate
- hydrogen
- oso2r11
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention comprises compounds having the general formula: <FORM:0946579/C2/1> wherein A represents hydroxyl, - OPO3H2, OSO2R11 wherein R11 is an alkly or aryl radical, or OAcyl the term Acyl representing the acyl radical of an organic carboxylic acid, R1 represents a b -hydroxy or keto group, X represents <FORM:0946579/C2/2> or <FORM:0946579/C2/3> , R being attached at the 2-position and representing hydrogen or methyl and Z represents hydrogen, methyl or fluorine provided that when X represents -CH=CH- or -CH2-CH2-, Z represents methyl or fluorine, pharmacologically acceptable water-suloble salts thereof pharmaceutical compositions thereof and a process for the preparation thereof by subjecting a compound having the formula: <FORM:0946579/C2/4> to oxidative hydroxylation and then, if desired, hydrolysing and/or oxidising to produce the corresponding free 21-hydroxy compound and 11-keto derivative subsequently the 21-hydroxy compound may be treated with an alkyl or aryl sulphonyl halide to obtain a 21-OSO2R11 compound which may be treated with an alkali metal iodide to obtain a 21-iodo compound or silver dihydrogen phosphate to obtain a 21-OPO3 H2 compound; treating the 21-OSO2R11 or the 21-iodo compound with a metal fluoride produces the 21-fluoro compounds. Alternatively the 21-phosphate is obtained by treating the 21-sulphonate with phosphoric acid in the presence of a tertiary amine and then acidifying the 21-hydrogen phosphate so produced to obtain the free 21-phosphate compound. The oxidative hydroxylation may be effected using osmium tetroxide and an oxidising agent e.g. hydrogen peroxide, an alkyl peroxide or an amine peroxide. The starting compound is obtained by reacting a compound having the formula: <FORM:0946579/C2/5> wherein Ac,X and Z are as defined above, with selenium dioxide to give a compound of the formula: <FORM:0946579/C2/6> and converting the latter compound to a compound having the formula: <FORM:0946579/C2/7> wherein Y is chlorine or bromine, by treatment with thionyl chloride or thionyl bromide, reacting the latter compound with a base in the presence of an inert solvent to produce a compound having the general formula: <FORM:0946579/C2/8> reacting the latter compound with anhydrous fluoride in the presence of an inert solvent to give a compound having the general formula: <FORM:0946579/C2/9> and then acylating to produce the corresponding 21-ester. Said compositions having anti-inflammatory properties, are administered in conventional dosage forms such as pills, tablets, capsules, syrups. or elixirs for oral use, or in liquid forms as injectable products, or topically in the forms of ointments, creams or lotions, with or without coacting antibiotics or germicides. Specifications 850,833, 872,112 and 873,219 also are referred to.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US144960A | 1960-01-11 | 1960-01-11 | |
US3676060A | 1960-06-17 | 1960-06-17 | |
US51298A US3239544A (en) | 1960-08-23 | 1960-08-23 | 16-fluoro-11-hydroxy steroids of the pregnane series |
Publications (1)
Publication Number | Publication Date |
---|---|
GB946579A true GB946579A (en) | 1964-01-15 |
Family
ID=27356927
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB38029/62A Expired GB946579A (en) | 1960-01-11 | 1960-12-19 | Improvements in or relating to steroids and the manufacture thereof |
GB43596/60A Expired GB946576A (en) | 1960-01-11 | 1960-12-19 | Improvements in or relating to steroids |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB43596/60A Expired GB946576A (en) | 1960-01-11 | 1960-12-19 | Improvements in or relating to steroids |
Country Status (4)
Country | Link |
---|---|
BE (1) | BE598999A (en) |
CH (2) | CH407113A (en) |
FR (1) | FR1088M (en) |
GB (2) | GB946579A (en) |
-
1960
- 1960-12-19 GB GB38029/62A patent/GB946579A/en not_active Expired
- 1960-12-19 GB GB43596/60A patent/GB946576A/en not_active Expired
-
1961
- 1961-01-09 CH CH18261A patent/CH407113A/en unknown
- 1961-01-09 CH CH940665A patent/CH422774A/en unknown
- 1961-01-11 BE BE598999A patent/BE598999A/en unknown
- 1961-04-08 FR FR858158A patent/FR1088M/en active Active
Also Published As
Publication number | Publication date |
---|---|
FR1088M (en) | 1962-01-29 |
CH407113A (en) | 1966-02-15 |
GB946576A (en) | 1964-01-15 |
BE598999A (en) | 1961-07-11 |
CH422774A (en) | 1966-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1064284A (en) | Improvements in or relating to progesterone derivatives | |
GB902292A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB946579A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB901293A (en) | Improvements in or relating to steroids | |
GB1506833A (en) | 16-substituted steroids of the pregnane series and the preparation of such steroids | |
EP0003863B1 (en) | Novel androstadienes, processes for their preparation and pharmaceutical compositions containing them | |
GB946578A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB898295A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB946577A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB959792A (en) | Improvements in or relating to steroids | |
GB935116A (en) | New cyclopentanophenanthrene derivatives and processes for the production thereof | |
GB1022042A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB971608A (en) | 17ª-methyl steroids and their production and use | |
GB865673A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB881901A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB872483A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB878622A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB923945A (en) | Improvements in or relating to steroids and the manufacture thereof | |
US3819604A (en) | 6,9,21-trihalogenosteroids | |
GB874375A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB872112A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB907812A (en) | Improvements in or relating to steroids and the manufacture thereof | |
GB874213A (en) | Improvements in or relating to steroids and the manufacture thereof | |
US3652604A (en) | Halohydrins and process for the preparation thereof | |
GB873608A (en) | Improvements in or relating to steroids and the manufacture thereof |